OT OnKure Therapeutics, Inc. Stock: price and directors' dealings · United States · SEC (Form 4)Follow the OnKure Therapeutics, Inc. stock price and the full directors' dealings record of the company, a listed equity based in United States. Shares trade on the US market, under the authority of SEC (Form 4). Market capitalisation: €164m. The latest transaction was disclosed on 24 March 2026 (Cession). Among the most active insiders: Saccomano Nicholas A. Every trade is free.
Analyst consensus: bullish or bearish? Analysts rate OnKure Therapeutics, Inc. Strong Buy (bullish), based on 4 analysts. Average price target: US$19.50.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ Sigma AI Analysis Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 24 March 2026
All Executives26 Thresholds0 Prospectus0 Other0
Declarations 26 total
▼ President and CEO · Executives · 23 Mar 2026
86 shares @ US$4.1565 19.7% of flow Class A Common Stock SEC:0001609284-26-000001:0
▼ Chief Financial Officer · Executives · 23 Mar 2026
301 shares @ US$4.1565 19.5% of flow Class A Common Stock SEC:0001692747-26-000001:0
◆ Director · Executives · 31 Dec 2025
5,258 shares 0Class A Common Stock SEC:0001622769-26-000001:0
◆ Director · Executives · 31 Dec 2025
3,911 shares 0Class A Common Stock SEC:0001193125-26-000942:0
▼ Chief Financial Officer · Executives · 22 Dec 2025
302 shares @ US$2.9677 10.9% of flow Class A Common Stock SEC:0001692747-25-000004:0
▼ President and CEO · Executives · 22 Dec 2025
87 shares @ US$2.9677 11.1% of flow Class A Common Stock SEC:0001609284-25-000004:0
◆ Director · Executives · 30 Sept 2025
5,545 shares 0Class A Common Stock SEC:0001622769-25-000003:0
◆ Director · Executives · 30 Sept 2025
4,125 shares 0Class A Common Stock SEC:0001193125-25-228402:0
▼ Chief Financial Officer · Executives · 22 Sept 2025
303 shares @ US$2.6235 10.8% of flow Class A Common Stock SEC:0001692747-25-000003:0
▼ President and CEO · Executives · 22 Sept 2025
88 shares @ US$2.6235 11.1% of flow Class A Common Stock SEC:0001609284-25-000003:0
◆ Director · Executives · 30 Jun 2025
6,311 shares 0Class A Common Stock SEC:0001415889-25-019052:0
◆ Director · Executives · 30 Jun 2025
4,694 shares 0Class A Common Stock SEC:0000950170-25-093063:0
▼ President and CEO · Executives · 23 Jun 2025
88 shares @ US$2.3842 14.4% of flow Class A Common Stock SEC:0001415889-25-018235:0
▼ Chief Financial Officer · Executives · 23 Jun 2025
303 shares @ US$2.3842 13.9% of flow Class A Common Stock SEC:0001415889-25-018234:0
270,270 shares @ US$1.85 100.0% of flow Common Stock SEC:0000950170-25-074459:0
Canonical exit: 13 Aug 2025 (T+90) 1,813,439 shares @ US$1.8545 98.6% of flow Class A Common Stock SEC:0000929638-25-001950:0
24,300 shares @ US$1.985 1.4% of flow Class A Common Stock SEC:0000929638-25-001870:0
▼ Chief Financial Officer · Executives · 4 Apr 2025
1,278 shares @ US$3.3276 100.0% of flow Class A Common Stock SEC:0001415889-25-010418:0
▼ President and CEO · Executives · 4 Apr 2025
358 shares @ US$3.3276 100.0% of flow Class A Common Stock SEC:0001415889-25-010419:0
◆ Director · Executives · 31 Mar 2025
2,580 shares 0Class A Common Stock SEC:0000950170-25-049473:0
◆ Director · Executives · 31 Mar 2025
3,469 shares 0Class A Common Stock SEC:0001415889-25-009659:0
345,739 shares Common Stock SEC:0001373604-24-000100:0
◆ Chief Financial Officer · Executives · 4 Oct 2024
16,331 shares Class A Common Stock SEC:0001415889-24-024918:0
◆ President and CEO · Executives · 4 Oct 2024
4,556 shares Class A Common Stock SEC:0001415889-24-024921:0
◆ Director · Executives · 4 Oct 2024
4,065 shares Class A Common Stock SEC:0001415889-24-024912:1
25 of 26 declarations
Load more (1 remaining) 关于 OnKure Therapeutics, Inc. OnKure Therapeutics, Inc. 是一家生物制药公司，专注于开发创新的癌症治疗方法。该公司专门从事靶向疗法的发现和开发，以改善患者预后。